newsfilter
← Latest News
Business Wire·

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

Abstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that six